PRESS RELEASE published on 02/01/2024 at 12:30, 2 years ago Immunic to Participate in Investor and Scientific Conferences in February Immunic, Inc. (Nasdaq: IMUX) to participate in BioCapital Europe 2024 and ACTRIMS Forum 2024 in February and March, presenting clinical pipeline therapies and poster presentations Immunic, Inc. BioCapital Europe 2024 ACTRIMS Forum 2024 Clinical Pipeline Therapies Poster Presentations
PRESS RELEASE published on 11/02/2023 at 11:30, 2 years 3 months ago Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts
PRESS RELEASE published on 10/26/2023 at 12:30, 2 years 3 months ago Immunic to Participate in Scientific and Industry Conferences in November
PRESS RELEASE published on 10/16/2023 at 12:30, 2 years 3 months ago Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023
PRESS RELEASE published on 10/15/2023 at 12:30, 2 years 3 months ago Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023
PRESS RELEASE published on 10/11/2023 at 12:30, 2 years 3 months ago Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting
PRESS RELEASE published on 10/09/2023 at 22:01, 2 years 4 months ago Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
PRESS RELEASE published on 10/04/2023 at 12:30, 2 years 4 months ago Immunic to Participate in Scientific Conferences in October
PRESS RELEASE published on 09/06/2023 at 12:30, 2 years 5 months ago Immunic to Participate in Industry and Investor Conferences in September
PRESS RELEASE published on 08/17/2023 at 12:30, 2 years 5 months ago Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
Published on 02/10/2026 at 15:00, 25 minutes ago Haven Safety AI Launches AI-Native Safety Intelligence Platform Co-Founded with The AES Corporation and AI Fund
Published on 02/10/2026 at 14:30, 55 minutes ago Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
Published on 02/10/2026 at 14:00, 1 hour 25 minutes ago Horizon Aircraft Partners with North Aircraft Industries to Manufacture the Wings for the Cavorite X7
Published on 02/10/2026 at 14:00, 1 hour 25 minutes ago BTU Metals Initiates Geophysical Program at Its Dixie East Property in Red Lake in Preparation for Drilling Drilling Planned for Three Ontario Gold Projects in 2026
Published on 02/10/2026 at 15:15, 10 minutes ago Kasowitz and Mishcon de Reya Comment on Tirana Mayor Erion Veliaj's Year in Detention: For 365 Days and Counting, Mayor Veliaj Suffers Denials of Due Process Rights and Apparent Political Persecution
Published on 02/10/2026 at 15:09, 16 minutes ago Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 02/10/2026 at 15:07, 17 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 02/09/2026 at 18:00, 21 hours 25 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 janvier 2026
Published on 02/09/2026 at 17:45, 21 hours 40 minutes ago Declaration of voting rights at the end of January 2026
Published on 02/09/2026 at 17:45, 21 hours 40 minutes ago DAMARTEX / Droits de vote bruts et réels au 31 janvier 2026
Published on 02/09/2026 at 17:45, 21 hours 40 minutes ago Déclaration des droits de vote à fin janvier 2026
Published on 02/09/2026 at 17:45, 21 hours 40 minutes ago Déclaration des droits de vote à fin janvier 2026
